BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29788429)

  • 1. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.
    Arvold ND; Armstrong TS; Warren KE; Chang SM; DeAngelis LM; Blakeley J; Chamberlain MC; Dunbar E; Loong HH; Macdonald DR; Reardon DA; Vogelbaum MA; Yuan Y; Weller M; van den Bent M; Wen PY
    Neuro Oncol; 2018 Jun; 20(7):897-906. PubMed ID: 29788429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
    Nayak L; DeAngelis LM; Brandes AA; Peereboom DM; Galanis E; Lin NU; Soffietti R; Macdonald DR; Chamberlain M; Perry J; Jaeckle K; Mehta M; Stupp R; Muzikansky A; Pentsova E; Cloughesy T; Iwamoto FM; Tonn JC; Vogelbaum MA; Wen PY; van den Bent MJ; Reardon DA
    Neuro Oncol; 2017 May; 19(5):625-635. PubMed ID: 28453751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response Assessment in Neuro-Oncology Clinical Trials.
    Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
    J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.
    Huang RY; Wen PY
    Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):705-718. PubMed ID: 27742111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Neurologic Assessment in Neuro-Oncology (NANO) Scale as an Assessment Tool for Survival in Patients With Primary Glioblastoma.
    Ung TH; Ney DE; Damek D; Rusthoven CG; Youssef AS; Lillehei KO; Ormond DR
    Neurosurgery; 2019 Mar; 84(3):687-695. PubMed ID: 29618103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging Criteria in Neuro-oncology.
    Nowosielski M; Wen PY
    Semin Neurol; 2018 Feb; 38(1):24-31. PubMed ID: 29548049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of steroids in neuro-oncology].
    Barbero-Bordallo N; Gomez-Vicente L
    Rev Neurol; 2019 May; 68(9):389-397. PubMed ID: 31017292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of tumor enhancement and brain edema in computerized tomography by corticosteroids: case report.
    Gerber AM; Savolaine ER
    Neurosurgery; 1980 Mar; 6(3):282-4. PubMed ID: 7383292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
    Vogelbaum MA; Jost S; Aghi MK; Heimberger AB; Sampson JH; Wen PY; Macdonald DR; Van den Bent MJ; Chang SM
    Neurosurgery; 2012 Jan; 70(1):234-43; discussion 243-4. PubMed ID: 21593697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.
    Huang RY; Bi WL; Weller M; Kaley T; Blakeley J; Dunn I; Galanis E; Preusser M; McDermott M; Rogers L; Raizer J; Schiff D; Soffietti R; Tonn JC; Vogelbaum M; Weber D; Reardon DA; Wen PY
    Neuro Oncol; 2019 Jan; 21(1):26-36. PubMed ID: 30137421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.
    Menzies-Gow A; Gurnell M; Heaney LG; Corren J; Bel EH; Maspero J; Harrison T; Jackson DJ; Price D; Lugogo N; Kreindler J; Burden A; de Giorgio-Miller A; Padilla K; Martin UJ; Garcia Gil E
    Lancet Respir Med; 2022 Jan; 10(1):47-58. PubMed ID: 34619104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
    Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
    J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Brain Tumor Response: RANO and Its Offspring.
    Eisele SC; Wen PY; Lee EQ
    Curr Treat Options Oncol; 2016 Jul; 17(7):35. PubMed ID: 27262709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
    Sharma M; Juthani RG; Vogelbaum MA
    Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee.
    Warren KE; Vezina G; Poussaint TY; Warmuth-Metz M; Chamberlain MC; Packer RJ; Brandes AA; Reiss M; Goldman S; Fisher MJ; Pollack IF; Prados MD; Wen PY; Chang SM; Dufour C; Zurakowski D; Kortmann RD; Kieran MW
    Neuro Oncol; 2018 Jan; 20(1):13-23. PubMed ID: 28449033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Relevance of Steroid Use in Neuro-Oncology.
    Ly KI; Wen PY
    Curr Neurol Neurosci Rep; 2017 Jan; 17(1):5. PubMed ID: 28138871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
    Okada H; Weller M; Huang R; Finocchiaro G; Gilbert MR; Wick W; Ellingson BM; Hashimoto N; Pollack IF; Brandes AA; Franceschi E; Herold-Mende C; Nayak L; Panigrahy A; Pope WB; Prins R; Sampson JH; Wen PY; Reardon DA
    Lancet Oncol; 2015 Nov; 16(15):e534-e542. PubMed ID: 26545842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
    Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
    J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.